Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Invested Capital (2016 - 2025)

Avalo Therapeutics' Invested Capital history spans 12 years, with the latest figure at $83.0 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 37.74% year-over-year to $83.0 million; the TTM value through Dec 2025 reached $83.0 million, down 37.74%, while the annual FY2025 figure was $83.0 million, 37.74% down from the prior year.
  • Invested Capital reached $83.0 million in Q4 2025 per AVTX's latest filing, down from $91.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $133.4 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
  • Average Invested Capital over 5 years is $27.3 million, with a median of $17.9 million recorded in 2023.
  • The largest YoY upside for Invested Capital was 1726.29% in 2024 against a maximum downside of 1695.79% in 2024.
  • A 5-year view of Invested Capital shows it stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then soared by 1726.29% to $133.4 million in 2024, then tumbled by 37.74% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Invested Capital are $83.0 million (Q4 2025), $91.5 million (Q3 2025), and $104.9 million (Q2 2025).